V
Vital Therapies
Developing a cell-based therapy targeting the treatment of acute liver failure
About Vital Therapies
Vital Therapies, Inc. was a San Diego-based biotherapeutic company focused on developing treatments for acute liver failure. Founded in May 2003, the company emerged by acquiring the assets of VitaGen, which itself was a successor to Hepatix Inc., the original developer of the ELAD technology since 1991. The company's core focus was the ELAD® System, an extracorporeal human allogeneic cellular liver therapy.
The ELAD System was designed as an external device to supplement liver function for patients with severe liver failure, aiming to provide a bridge-to-transplant or allow the patient's own liver to regenerate. The technology utilized proprietary VTL C3A cells, an immortal human liver-derived cell line, housed in cartridges through which the patient's blood would be filtered. This system was intended to metabolize toxins and deliver essential proteins, mimicking the functions of a healthy liver. The business model was centered on the successful development and commercialization of this single product candidate, targeting a market with a significant unmet need due to the shortage of donor livers for transplantation.
Despite decades of development and multiple clinical trials, the ELAD System repeatedly failed to demonstrate statistically significant improvements in patient survival rates. A pivotal Phase III trial, VTI-208, did not meet its primary or secondary endpoints in 2015. Subsequently, another Phase III study, VTL-308, also failed to show a significant improvement in overall survival through 91 days. Following this second major trial failure in September 2018, Vital Therapies announced it would cease all further development of the ELAD System. The company concluded that regulatory approval in the U.S. or Europe was unlikely without substantial additional capital and time for more trials.
After halting its primary research program, Vital Therapies began exploring strategic alternatives to enhance stockholder value. In January 2019, the company announced a definitive agreement for a reverse merger with Immunic AG, a private German clinical-stage biotechnology company. The all-stock transaction was completed in April 2019, after which Vital Therapies was renamed Immunic, Inc. and began trading under the new ticker symbol "IMUX". The newly formed entity shifted its focus to Immunic's pipeline of treatments for chronic inflammatory and autoimmune diseases, with former Vital Therapies stockholders owning approximately 11.75% of the combined company.
Source: Dealroom company dataNews
Open roles
Vital Therapies in the San Diego ecosystem
The Vital Therapies office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Tech Coast Angels
Series B and later3 investors entered at this stage
Versant Ventures- DDDFJ DragonFund
Delphi Ventures
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Vital Therapies on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Vital Therapies on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.
